IL2 and neoplasm: Besides molecule production by tumor residence cells, immune cells at the tumor site can modulate NK cell function by competing for IL-2 or inhibiting NK cell IL-2-mediated activation via cell-to-cell contact (Sitrin et al., 2013; Sprinzl et al., 2013).